Abstract 545P
Background
Immune checkpoint inhibitors (ICI) are standard of care in advanced non-small cell lung cancer (NSCLC) without driver mutations. A small proportion of patients (pts) treated with ICIs will achieve durable responses. We describe outcomes of a real-world cohort of pts who completed two years of pembrolizumab (pembro).
Methods
Clinical data of pts who completed 35 cycles of first-line pembro for NSCLC (or 30-34 cycles with reason for cessation other than progression) was collected retrospectively from sites across Australia via the AUstralian Registry and biObank of thoRacic cAncers (AURORA). Primary endpoints were progression rate post pembro completion and progression free survival (PFS). Local treatment of oligoprogressive disease during pembro was included. Analyses were performed using R.
Results
71 pts from six centres with a median age of 66.0 yrs, 49% male & 90% ECOG≤1 were identified. Pts were Caucasian (82%) or Asian (16%); past (69%) or current (25%) smokers with a mean 37 pack year history. Histology comprised 73% adenocarcinoma, 16% squamous. 18 pts (25%) had brain mets at diagnosis, 16 treated (8 resected, 8 RT). Median PD-L1 tumour proportion score (TPS) was 68%; 12 pts (17%) PD-L1 negative, 43 pts (61%) TPS≥50%. No pts had ALK/ROS/EGFR mutations; 29/49 tested (60%) had K-Ras mutations. Median follow up from pembro start was 38.7 months (24.5 – 65.6). Table: 545P
Total population (n=71) | |||
Pembro | 39 (55%) | Median time on pembro | 24.2 mo |
Pembro + chemo | 32 (45%) | (20.0-35.3) | |
Objective Response Rate (ORR) | 78.6% | 76.9% | |
CR | 20 (29%) | ORR pembro | 80.6% |
PR | 35 (50%) | ORR pembro+chemo | p=0.86 |
Median PFS | 46.1 mo (95%CI 39.5-NR) | PFS in PD-L1≥1%PFS in PD-L1 neg | NR (46.1-NR)28.1 mo (16.3-NR)p=0.013 |
Oligoprogression during pembro | |||
Total | 17 (24%) | ||
Locoregional | 8 | PFS oligo subgroup | 12.0 mo (9.4-18.9) |
Brain | 7 | PFS2 | 23.1 mo (20.2-NR) |
Progression post pembro | |||
Total | 20 (28%) | Median time to progression | 3.3 mo (1.0-26.3) |
Locoregional | 11 | ||
Brain | 3 | ||
Bone | 5 | ||
PD-L1≥1% | 13 | Pts with CR | 2 |
PD-L1 neg | 6 (OR 3.46, p=0.06) | Pts without CR | 18 (OR 5.06, p=0.04) |
Brain mets at diagnosis (n=18) | |||
CNS progression | 6 (33%) |
Conclusions
Pts completing two years of pembro for NSCLC in Australia had high rates of K-Ras mutation and PD-L1 expression; a significant proportion had brain metastases and treated oligoprogression. Progression rate post pembro was higher in PD-L1-negative pts and in those without complete response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AURORA (AUstralian Registry and biObank of thoRacic cAncers) national database. Each participating hospital in various sites throughout Australia had ethics approval to contribute to the AURORA database via their local ethics committee.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract